Fgf20-KO Mouse
一般名
Fgf20-KO
製品ID
S-KO-15313
背景情報
C57BL/6NCya
系統ID
KOCMP-80857-Fgf20-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Fgf20-KO Mouse(カタログ番号S-KO-15313)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Fgf20-KO
系統ID
KOCMP-80857-Fgf20-B6N-VA
遺伝子名
製品ID
S-KO-15313
遺伝子別名
Fgf4a
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 8
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000034014
NCBIトランスクリプトID
NM_030610
ターゲット領域
Exon 1~3
有効領域の大きさ
~7.6 kb
遺伝子研究の概要
Fgf20, or Fibroblast growth factor 20, is a neurotrophic factor and a member of the FGF9 subfamily. Its receptors include FGFR4, FGFR3b, FGFR2b, and FGFRc splice forms. It is highly expressed in the adult brain and is expressed in various regions during embryonic development. Fgf20 is associated with multiple biological processes and human diseases [1].
Fgf20 knockout (KO) mouse models have shown a variety of phenotypes. For example, Fgf20 KO mice exhibit congenital deafness, lack of hair, small kidneys, and delayed mammary ductal outgrowth, indicating its role in inner ear, hair, kidney, and mammary gland development [1]. In the cochlea, FGF20-FGFR1 signaling through MAPK and PI3K controls sensory progenitor differentiation, as shown by experiments inhibiting pathways downstream of FGFR1 in cochlea explant cultures [2]. In spinal cord injury mouse models, recombinant human FGF20 was found to mitigate necroptosis, reduce neural functional deficits, and promote repair [3]. In a traumatic brain injury mouse model, FGF20 reduced neurofunctional deficits, brain edema, and neuroinflammation, protecting the blood-brain barrier integrity [5]. Fgf20 KO mice also show skeletal dysmorphology and mineralization defects, especially in the spine and fingers, indicating its role in skeletal development and bone homeostasis [7].
In conclusion, Fgf20 plays essential roles in multiple biological processes such as embryonic development, organogenesis, and neural repair. The study of Fgf20 using KO mouse models has provided insights into its functions in diseases like congenital deafness, Parkinson's disease, cancer, and inflammatory bowel disease, suggesting its potential as a therapeutic target in these disease areas [1,3,5,7].
References:
1. Van Greenen, Justine D, Hockman, Dorit. 2023. FGF20. In Differentiation; research in biological diversity, 139, 100737. doi:10.1016/j.diff.2023.10.005. https://pubmed.ncbi.nlm.nih.gov/38007375/
2. Su, Yutao, Yang, Lu M, Ornitz, David M. 2020. FGF20-FGFR1 signaling through MAPK and PI3K controls sensory progenitor differentiation in the organ of Corti. In Developmental dynamics : an official publication of the American Association of Anatomists, 250, 134-144. doi:10.1002/dvdy.231. https://pubmed.ncbi.nlm.nih.gov/32735383/
3. Cai, Xiong, Xie, Zhenwen, Zhao, Juan, Xu, Jiake, Zhu, Sipin. . FGF20 promotes spinal cord injury repair by inhibiting the formation of necrotic corpuscle P-MLKL/P-RIP1/P-RIP3 in neurons. In Journal of cellular and molecular medicine, 28, e70109. doi:10.1111/jcmm.70109. https://pubmed.ncbi.nlm.nih.gov/39676730/
4. Katoh, Masaru. 2018. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). In International journal of molecular medicine, 42, 713-725. doi:10.3892/ijmm.2018.3689. https://pubmed.ncbi.nlm.nih.gov/29786110/
5. Chen, Jun, Wang, Xue, Hu, Jian, Lin, Li, Li, Xiaokun. 2021. FGF20 Protected Against BBB Disruption After Traumatic Brain Injury by Upregulating Junction Protein Expression and Inhibiting the Inflammatory Response. In Frontiers in pharmacology, 11, 590669. doi:10.3389/fphar.2020.590669. https://pubmed.ncbi.nlm.nih.gov/33568994/
6. Wang, Xiaoli, Sun, Xiaoxuan, Zhang, Xiaona, Li, Hong, Xie, Anmu. 2017. Quantitative assessment of the effect of FGF20 rs12720208 variant on the risk of Parkinson's disease: a meta-analysis. In Neurological research, 39, 374-380. doi:10.1080/01616412.2017.1286542. https://pubmed.ncbi.nlm.nih.gov/28191856/
7. Dlugosova, Sylvie, Spoutil, Frantisek, Madureira Trufen, Carlos Eduardo, Sedlacek, Radislav, Prochazka, Jan. 2024. Skeletal dysmorphology and mineralization defects in Fgf20 KO mice. In Frontiers in endocrinology, 15, 1286365. doi:10.3389/fendo.2024.1286365. https://pubmed.ncbi.nlm.nih.gov/39129916/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
